For example, daily administration of low doses interleukin 2 (IL-2) has been linked to expansion of Treg cells and amelioration of graft-vs-host disease as well as induction of remission in systemic lupus erythematosus (SLE) and type I diabetes. Here, IL2 is linked to systemic lupus erythematosus.